AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12038448 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step high-dose chemotherapy (HDT)
Number of subjects: 20
Study 12038448 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of molecular disease in CR patients by PCR
Number of subjects: 20
Study 10633637 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation risk assessment scale and bowel management protocol
Number of subjects: 0
Study 7786834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 35
Study 7786834 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 35
Study 2132893 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal model (visual demonstration with verbal cues)
Number of subjects: 80
Study 2132893 — intervention group
Group type: COMPARATOR
Intervention: No model (verbal instructions only)
Number of subjects: 80
Study 7468558 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 55
Study 7468558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 7468558 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide vs Placebo
Number of subjects: 55
Study 31397703 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-fragment plating (single 3.5-mm locking compression plate)
Number of subjects: 123
Study 31397703 — intervention group
Group type: COMPARATOR
Intervention: Mini-fragment plating (orthogonal plating with 2.7-mm reconstruction plates)
Number of subjects: 123
Study 31397703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-fragment plating
Number of subjects: 123
Study 31397703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 123
Study 31397703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study 28270329 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal homework adherence
Number of subjects: 0
Study 28270329 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate imaginal homework adherence (two or more times a week)
Number of subjects: 0
Study 28270329 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ratings of helpfulness of both types of homework
Number of subjects: 0
Study 28270329 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo homework adherence
Number of subjects: 0
Study 26172895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 4.2 g twice daily
Number of subjects: 306
Study 26172895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 8.4 g twice daily
Number of subjects: 306
Study 26172895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 12.6 g twice daily
Number of subjects: 306
Study 26172895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 8.4 g twice daily (moderate hyperkalemia)
Number of subjects: 306
Study 26172895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 12.6 g twice daily (moderate hyperkalemia)
Number of subjects: 306
Study 26172895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 16.8 g twice daily (moderate hyperkalemia)
Number of subjects: 306
Study 26172895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (all doses)
Number of subjects: 306
Study 23325525 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchman device
Number of subjects: 707
Study 23325525 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 707
Study 21299902 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 168
Study 21299902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 19889888 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SAE summary
Number of subjects: 806
Study 16441622 — intervention group
Group type: EXPERIMENTAL
Intervention: BMV 0.1% tape
Number of subjects: 42
Study 16441622 — intervention group
Group type: COMPARATOR
Intervention: BMV 0.12% cream
Number of subjects: 42
Study 15313287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.4% ophthalmic solution (Acular(R) LS), n = 156, 4 times daily for up to 4 days
Number of subjects: 313
Study 15313287 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control), n = 157, 4 times daily for up to 4 days
Number of subjects: 313
Study 11744142 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients
Number of subjects: 88
Study 9468005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (LS)
Number of subjects: 36
Study 9468005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potassium diet (HK)
Number of subjects: 36
Study 9468005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium diet (HCa)
Number of subjects: 36
Study 9468005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-sodium, high-potassium, high-calcium diet (LS, HK, HCa)
Number of subjects: 36
Study 8512397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural fentanyl
Number of subjects: 30
Study 8512397 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural fentanyl
Number of subjects: 30
Study 2455111 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine treatment
Number of subjects: 10
Study 29689482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adventure-based training programme (4-day duration)
Number of subjects: 222
Study 29689482 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 222
Study 27406346 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib added to standard neoadjuvant chemotherapy
Number of subjects: 193
Study 27406346 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy with trastuzumab (Control)
Number of subjects: 193
Study 24927078 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-antagonist protocol
Number of subjects: 80
Study 24927078 — intervention group
Group type: COMPARATOR
Intervention: long‐GnRH‐agonist protocol
Number of subjects: 80
Study 21880023 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week exercise program including aerobic and strengthening exercises, conducted between week 20 and 36 of pregnancy, with one weekly group session led by physiotherapists and home exercises encouraged twice a week.
Number of subjects: 855
Study 21880023 — intervention group
Group type: COMPARATOR
Intervention: Regular antenatal care (Control)
Number of subjects: 855
Study 20557387 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 60
Study 20557387 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-massage
Number of subjects: 60
Study 20557387 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional massage
Number of subjects: 60
Study 20557387 — intervention group
Group type: COMPARATOR
Intervention: Control group (laxatives)
Number of subjects: 60
Study 18407413 — intervention group
Group type: EXPERIMENTAL
Intervention: Leech therapy (2-3 locally applied leeches)
Number of subjects: 32
Study 18407413 — intervention group
Group type: COMPARATOR
Intervention: Topical diclofenac (30-day course, twice a day)
Number of subjects: 32
Study 18407413 — intervention group
Group type: EXPERIMENTAL
Intervention: Leech therapy
Number of subjects: 32
Study 16598181 — intervention group
Group type: EXPERIMENTAL
Intervention: Scene 2 (environment where the patient feels strong anxiety)
Number of subjects: 57
Study 16598181 — intervention group
Group type: COMPARATOR
Intervention: Scene 1 (environment where the patient feels safe and comfortable)
Number of subjects: 57
Study 11874430 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (15 mg/day)
Number of subjects: 24
Study 11874430 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (6 mg/day)
Number of subjects: 24
Study 11874430 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1500 mg/day)
Number of subjects: 24
Study 10195783 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine alone
Number of subjects: 301
Study 10195783 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine with immune globulin (Ig) concurrently
Number of subjects: 301
Study 10195783 — intervention group
Group type: COMPARATOR
Intervention: Ig alone
Number of subjects: 301
Study 7851164 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 225
Study 7851164 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and surgical treatment
Number of subjects: 225
Study 7851164 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (anal surgeries including abscess drainage and fistulotomy)
Number of subjects: 225
Study 7851164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal surgery for rectovaginal fistulas
Number of subjects: 225
Study 7851164 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of anal disease requiring further surgery
Number of subjects: 225
Study 2341995 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial emotional upset
Number of subjects: 283
Study 2341995 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed emotional reaction
Number of subjects: 283
Study 2341995 — intervention group
Group type: EXPERIMENTAL
Intervention: Low average levels of emotional upset
Number of subjects: 283
Study 2341995 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of initial emotional upset that subsided
Number of subjects: 283
Study 2341995 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of emotional distress long-term follow-up
Number of subjects: 283
Study 2341995 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to achieve long-term emotional readjustment
Number of subjects: 283
Study 387010 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide intranasal spray
Number of subjects: 67
Study 387010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 31687867 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-delivered mirror visual feedback (VR-MVF) and exposure therapy (VR-ET)
Number of subjects: 14
Study 31687867 — intervention group
Group type: COMPARATOR
Intervention: Non-embodied virtual reality sessions (control)
Number of subjects: 14
Study 28556616 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 43
Study 26848148 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg LD/10 mg MD q.d.)
Number of subjects: 110
Study 26848148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg LD/90 mg MD b.i.d)
Number of subjects: 110
Study 26848148 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (previous treatment)
Number of subjects: 110
Study 25452426 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 125/25 mcg
Number of subjects: 0
Study 25452426 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 0
Study 25452426 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 0
Study 25452426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22238169 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin PEP
Number of subjects: 86
Study 22238169 — intervention group
Group type: COMPARATOR
Intervention: No PEP (daily symptom monitoring)
Number of subjects: 86
Study 22238169 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Azithromycin PEP vs No PEP
Number of subjects: 86
Study 22238169 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 86
Study 20028938 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% intralipid infusion at 40 ml/h for 48 h
Number of subjects: 25
Study 18158504 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2166
Study 18158504 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 2166
Study 16010209 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous stem cell transplantation (HDT-ASCT)
Number of subjects: 575
Study 16010209 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 575
Study 12711469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation
Number of subjects: 56
Study 12711469 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen-ultraviolet A (PUVA)
Number of subjects: 56
Study 12711469 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar
Number of subjects: 56
Study 12711469 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Number of subjects: 56
Study 10663427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 g/kg of 10% (v/v) alcohol solution
Number of subjects: 10
Study 10663427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g/kg of 10% (v/v) alcohol solution
Number of subjects: 10
Study 10663427 — intervention group
Group type: COMPARATOR
Intervention: 0.00 g/kg of 10% (v/v) alcohol solution
Number of subjects: 10
Study 10663427 — intervention group
Group type: COMPARATOR
Intervention: 0.25 g/kg of 10% (v/v) alcohol solution
Number of subjects: 10
Study 8680488 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 0
Study 8680488 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0
Study 8680488 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0
Study 8680488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1298086 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg total dose of artemether given over 5 days
Number of subjects: 167
Study 1298086 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg total dose of artemether given over 5 days
Number of subjects: 167
Study 1298086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosage regimens (480 mg and 600 mg)
Number of subjects: 167
Study 6094446 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intravenous injection of cefotaxime at the time of induction of anaesthesia
Number of subjects: 66
Study 6094446 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 66
Study 30043658 — intervention group
Group type: EXPERIMENTAL
Intervention: ozanimod hydrochloride 0.5 mg
Number of subjects: 249
Study 30043658 — intervention group
Group type: EXPERIMENTAL
Intervention: ozanimod hydrochloride 1 mg
Number of subjects: 249
Study 30043658 — intervention group
Group type: COMPARATOR
Intervention: placebo → ozanimod hydrochloride 0.5 mg
Number of subjects: 249
Study 30043658 — intervention group
Group type: COMPARATOR
Intervention: placebo → ozanimod hydrochloride 1 mg
Number of subjects: 249
Study 30043658 — intervention group
Group type: EXPERIMENTAL
Intervention: ozanimod treatment
Number of subjects: 249
Study 30272388 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended SPRINT BP measurements (139.77 ± 19.22/75.42 ± 11.72 mm Hg)
Number of subjects: 65
Study 30272388 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended SPRINT BP measurements
Number of subjects: 65
Study 30272388 — intervention group
Group type: COMPARATOR
Intervention: Unobserved SPRINT-like BP measurements
Number of subjects: 65
Study 27004517 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT service improvement programme over a 1-year period
Number of subjects: 25
Study 27004517 — intervention group
Group type: COMPARATOR
Intervention: No service improvement programme
Number of subjects: 25
Study 25220298 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM crowns
Number of subjects: 15
Study 25220298 — intervention group
Group type: COMPARATOR
Intervention: Heat-pressed crowns
Number of subjects: 15
Study 25220298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 22623206 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training for 30 minutes, 3 days/week for 4 weeks
Number of subjects: 30
Study 22623206 — intervention group
Group type: COMPARATOR
Intervention: Lokomat training for 30 minutes, 3 days/week for 4 weeks
Number of subjects: 30
Study 20354057 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme (10-day duration, focused on enhancing functional capacity)
Number of subjects: 86
Study 20354057 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (including standard physiotherapy)
Number of subjects: 86
Study 18848676 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families program (n = 369)
Number of subjects: 667
Study 18848676 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 298)
Number of subjects: 667
Study 15864148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and motivational program
Number of subjects: 93
Study 15864148 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 93
Study 12093068 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Treatment (MT) for stroke prevention including antiplatelet agents, lipid-lowering drugs, diabetic and hypertension control.
Number of subjects: 219
Study 10530683 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 10530683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0
Study 10530683 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agents
Number of subjects: 0
Study 10530683 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 8538490 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined therapy
Number of subjects: 151
Study 8538490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 151
Study 8538490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 1754608 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 1754608 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 0
Study 1754608 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 1754608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6372981 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 176
Study 6372981 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-thioguanine (6-TG)
Number of subjects: 176
Study 6372981 — intervention group
Group type: COMPARATOR
Intervention: 6-thioguanine (6-TG) in nonrandomized arm for previously drug-resistant tumors
Number of subjects: 176
Study 6372981 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) after failing 6-TG
Number of subjects: 176
Study 6372981 — intervention group
Group type: COMPARATOR
Intervention: 6-thioguanine (6-TG) after failing 5-FU
Number of subjects: 176
Study 31673419 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day monotherapy
Number of subjects: 0
Study 31673419 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day + MTX
Number of subjects: 0
Study 31673419 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab (ADA) 40 mg every other week + MTX
Number of subjects: 0
Study 31673419 — intervention group
Group type: COMPARATOR
Intervention: tofacitinib monotherapy
Number of subjects: 0
Study 29807091 — intervention group
Group type: EXPERIMENTAL
Intervention: MR‐proADM biomarker
Number of subjects: 313
Study 29807091 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT biomarker
Number of subjects: 313
Study 29807091 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual triage algorithm with MR‐proADM cut-off of 0.80 nmol/L
Number of subjects: 313
Study 29807091 — intervention group
Group type: COMPARATOR
Intervention: Outpatients treated without hospitalization
Number of subjects: 313
Study 26967331 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 doses albendazole
Number of subjects: 60
Study 26967331 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses albendazole
Number of subjects: 60
Study 26967331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24867571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-as-you-speed (PAYS) intervention with intelligent speed assistance (ISA), 30% discount off insurance premium.
Number of subjects: 250
Study 24867571 — intervention group
Group type: COMPARATOR
Intervention: Control group with no feedback.
Number of subjects: 250
Study 19820030 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin (6.4 nmol/kg)
Number of subjects: 10
Study 19820030 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 10
Study 15449641 — intervention group
Group type: EXPERIMENTAL
Intervention: IWQOL-Lite
Number of subjects: 1972
Study 15449641 — intervention group
Group type: EXPERIMENTAL
Intervention: IWQOL-Lite with age and BMI included
Number of subjects: 1972
Study 11289328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventolin CFC
Number of subjects: 313
Study 11289328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventolin HFA
Number of subjects: 313
Study 11289328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 9251955 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal perineoplasty and interferon (IFN) injections
Number of subjects: 19
Study 9251955 — intervention group
Group type: COMPARATOR
Intervention: Total perineoplasty
Number of subjects: 19
Study 8126628 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with surfactant (Curosurf) at a dosage of 200 mg/kg
Number of subjects: 182
Study 3631319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 40
Study 3631319 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 40
Study 3631319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ascorbic acid and haloperidol
Number of subjects: 40
Study 3631319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31858658 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cosmetic product combination (CCP)
Number of subjects: 43
Study 31858658 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone (HQ)
Number of subjects: 43
Study 30981961 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly tailored advice (weeks 3–11)
Number of subjects: 51
Study 30981961 — intervention group
Group type: COMPARATOR
Intervention: General RRI prevention advice (baseline)
Number of subjects: 51